Latest News !
 

Dr Boreham's Crucible: Antisense Therapeutics

Opthea Jumps 160% on OPT-302 Wet AMD Result

Victoria Innovation Minister Martin Pakula Talks Biotech

Bionomics BNC210 Fails 2nd Phase II Trial (Agitation)

Ausbiotech: 'Threat To R&D Incentive Worries Sector'

Minister Karen Andrews Talks Biotech

Orthocell Up 377% On 4-Patient Celgro Nerve Regeneration

Actinogen: 'Xanamem Fails Alzheimer's Endpoints'; Falls 71%

August BDI-40 Up 13%, Big Caps Up 3%,
ASX200 Down 3%, NBI Down 3% 

BDI-40 A '10-Bagger' Since Global Financial Crisis

 Opthea Up 341%, Polynovo 31%, Neuren 24%, Pro Medicus 21%;
Osprey Down 32%, Clinuvel 21%, Uscome 21%, Pharmaxis 18%

 

September 1, 2019

 

The graphs below tell it all. 

The adjusted Biotech Daily Top 40 Index (BDI-40) is at a record high, and since the Global Financial Crisis all-time low, is just shy of a “10-bagger”, up from $2,087 million at December 31, 2008, to an adjusted $18,413 million on Friday.

 

The unadjusted BDI-40 was up 13.1 percent in August, to a collective market capitalization of $14,288 million, the AX200 retreated 3.1 percent to 6,604 points, while the Nasdaq Biotechnology Index (NBI) fell a further 2.6 percent.

 

In August, the collective value of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) was up 3.2 percent to a record $148,614 million, despite Cochlear slipping 3.1 percent to $12,325 million. Resmed was up 8.6 percent to $29,579 million and CSL was up 2.6 percent to $106,710 million.

 

While 24 of the BDI-40 stocks fell, with just 11 up and five unchanged, the falls were mostly in the much smaller Second 20.

 

The Top 20 boasts four companies worth more than $1 billion each (see last page), including Pro Medicus at $3.8 billion, along with Avita, Mesoblast and Opthea most of the way to $1 billion each.

 

Opthea was the clear percentage best, on positive phase II Wet AMD trial results (BD: Aug 7, 2019), up 340.5 percent and adding $647 million to its market capitalization, but Pro Medicus added $654 million to the indices.

 

Polynovo quietly rose $330 million in August, up 31.2 percent to $1,388 million, followed by Neuren (24.2%), Pro Medicus (20.5%), Nanosonics (up $258m; 15.6%), Resonance (14.6%) and Immutep (14.1%).

 

Osprey continued to struggle, down just $10 million but 32.3 percent to $21 million. Clinuvel retreated $340 million or 21.4 percent to $1,252 million on the terrible news that its revenue was only up 22 percent to a record $31 million, with a record net profit after tax up 37 percent to $18 million - and it paid a dividend. That’s not very biotechy, is it?

 

Uscom also fell on good end-of-year news, down 21.1 percent to $15 million, followed by Pharmaxis (18%), Optiscan (16.7%), Next Science (16.4%), Starpharma (16.4%), Medical Developments (16.3%), Imugene (15.6%) and Proteomics (12.0%).

 

Cannabis Corner lost $300 million or 15.7 percent to $1,613 million, with 13 of the 18 falling, two unchanged and just three higher. Elixinol lost $169 million or 36.9 percent.

 

In the US, Queensland’s Protagonist jumped 34.7 percent to $508 million, Israel’s Redhill with Australian assets was up 16.4 percent to $319 million, Eyepoint (Psivida) was up 10.2 percent to $237 million, with Vaxart (Biota) up 6.25 percent to $17 million.

 

Outside the BDI-40, Painchek was up 523.3 percent from $30 million a year ago to $187 million, Alcidion climbed 321.2 percent for the year, Bluechiip put on 64.2 percent to $87 million in August, Mach7 passed the $100 million barrier and Mayne Pharma continued its slide, down 15.1 percent to $712 million for the month and 61.7 percent for the year.

 

 

BDI-40 v S&P ASX200 Jun 30, 2006 to Aug 31, 2019 

 

3-Year Big Caps (Cochlear, CSL, Resmed) to Aug 31, 2019

BDI-40 ($m) v S&P ASX200 – Year to Aug 31, 2019 (current, raw data)